These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26838084)

  • 1. Repeated Intraportal Injection of Mesenchymal Stem Cells in Combination with Pioglitazone in Patients with Compensated Cirrhosis: A Clinical Report of Two Cases.
    Vosough M; Moossavi S; Mardpour S; Akhlaghpoor S; Azimian V; Jarughi N; Hosseini SE; Ashrafi M; Nikfam S; Aghdami N; Malekzadeh R; Mohamadnejad M; Baharvand H
    Arch Iran Med; 2016 Feb; 19(2):131-6. PubMed ID: 26838084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis.
    Mohamadnejad M; Alimoghaddam K; Bagheri M; Ashrafi M; Abdollahzadeh L; Akhlaghpoor S; Bashtar M; Ghavamzadeh A; Malekzadeh R
    Liver Int; 2013 Nov; 33(10):1490-6. PubMed ID: 23763455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
    Wassef MAE; Tork OM; Rashed LA; Ibrahim W; Morsi H; Rabie DMM
    Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):27-38. PubMed ID: 28449155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study.
    Jang YO; Kim YJ; Baik SK; Kim MY; Eom YW; Cho MY; Park HJ; Park SY; Kim BR; Kim JW; Soo Kim H; Kwon SO; Choi EH; Kim YM
    Liver Int; 2014 Jan; 34(1):33-41. PubMed ID: 23782511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial.
    Kharaziha P; Hellström PM; Noorinayer B; Farzaneh F; Aghajani K; Jafari F; Telkabadi M; Atashi A; Honardoost M; Zali MR; Soleimani M
    Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1199-205. PubMed ID: 19455046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis.
    Kantarcıoğlu M; Demirci H; Avcu F; Karslıoğlu Y; Babayiğit MA; Karaman B; Öztürk K; Gürel H; Akdoğan Kayhan M; Kaçar S; Kubar A; Öksüzoğlu G; Ural AU; Bağcı S
    Turk J Gastroenterol; 2015 May; 26(3):244-50. PubMed ID: 26006200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease.
    Salama H; Zekri AR; Medhat E; Al Alim SA; Ahmed OS; Bahnassy AA; Lotfy MM; Ahmed R; Musa S
    Stem Cell Res Ther; 2014 May; 5(3):70. PubMed ID: 24886681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats.
    Li T; Zhu J; Ma K; Liu N; Feng K; Li X; Wang S; Bie P
    J Surg Res; 2013 Oct; 184(2):1161-73. PubMed ID: 23809154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis.
    Okunuki Y; Usui Y; Nakagawa H; Tajima K; Matsuda R; Ueda S; Hattori T; Kezuka T; Goto H
    Exp Eye Res; 2013 Nov; 116():291-7. PubMed ID: 24107513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients With Decompensated Cirrhosis: A Double-Blind Randomized Controlled Trial.
    Mohamadnejad M; Vosough M; Moossavi S; Nikfam S; Mardpour S; Akhlaghpoor S; Ashrafi M; Azimian V; Jarughi N; Hosseini SE; Moeininia F; Bagheri M; Sharafkhah M; Aghdami N; Malekzadeh R; Baharvand H
    Stem Cells Transl Med; 2016 Jan; 5(1):87-94. PubMed ID: 26659833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
    Werner C; Kamani CH; Gensch C; Böhm M; Laufs U
    Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial.
    Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC
    Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mesenchymal stem cells as perspective method of fibrosis/cirrhosis treatment].
    Lukashik SP; Aleĭnikova OV; Tsyrkunov VM; Isaĭkina IaI; Romanova ON; Shimanskiĭ AT; Kravchuk RI
    Eksp Klin Gastroenterol; 2013; (12):3-7. PubMed ID: 24933982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone, a peroxisome proliferator-activated receptor γ activator, suppresses coronary spasm.
    Morita S; Mizuno Y; Harada E; Kashiwagi Y; Yoshimura M; Murohara T; Yasue H
    Coron Artery Dis; 2014 Dec; 25(8):671-7. PubMed ID: 25025992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases.
    Liang J; Zhang H; Zhao C; Wang D; Ma X; Zhao S; Wang S; Niu L; Sun L
    Int J Rheum Dis; 2017 Sep; 20(9):1219-1226. PubMed ID: 28217916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis.
    Gholamrezanezhad A; Mirpour S; Bagheri M; Mohamadnejad M; Alimoghaddam K; Abdolahzadeh L; Saghari M; Malekzadeh R
    Nucl Med Biol; 2011 Oct; 38(7):961-7. PubMed ID: 21810549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function.
    Shinmura D; Togashi I; Miyoshi S; Nishiyama N; Hida N; Tsuji H; Tsuruta H; Segawa K; Tsukada Y; Ogawa S; Umezawa A
    Stem Cells; 2011 Feb; 29(2):357-66. PubMed ID: 21732492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell therapy in chronic liver disease.
    Takami T; Terai S; Sakaida I
    Curr Opin Gastroenterol; 2012 May; 28(3):203-8. PubMed ID: 22395569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis.
    Mohamadnejad M; Alimoghaddam K; Mohyeddin-Bonab M; Bagheri M; Bashtar M; Ghanaati H; Baharvand H; Ghavamzadeh A; Malekzadeh R
    Arch Iran Med; 2007 Oct; 10(4):459-66. PubMed ID: 17903050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.